75
Participants
Start Date
July 14, 2023
Primary Completion Date
April 30, 2027
Study Completion Date
April 30, 2030
gemcitabine, cisplatin and tislelizumab
"All patients will receive 2 cycles of gemcitabine and cisplatin (GP) + tislelizumab. Each cycle lasts 21 days. Treatment is given through an IV line on day 1 and 8.~After 2 cycles a FDG-PET-CT scan will be performed. Patients who respond well will proceed with 2 additional cycles of GP + tislelizumab . Patients with insufficient response will stop with the study treatment and they will continue treatment according to local practice.~After 4 cycles of GP + tislelizumab another FDG-PET-CT scan will be performed. If this scan shows that the disease is under control (metabolic complete remission) patients will proceed with 13 cycles of tislelizumab consolidation treatment (21 day cycles). Treatment is given on day 1 through an IV line."
RECRUITING
BE-Bruxelles-STLUC, Brussels
RECRUITING
DK-Aarhus N-AUH, Aarhus
RECRUITING
DK-Copenhagen-RIGSHOSPITALET, Copenhagen
RECRUITING
DK-Odense-OUH, Odense
RECRUITING
NL-Amersfoort-MEANDERMC, Amersfoort
RECRUITING
NL-Amsterdam-AMC, Amsterdam
RECRUITING
NL-Arnhem-RIJNSTATE, Arnhem
RECRUITING
NL-Eindhoven-MAXIMAMC, Eindhoven
RECRUITING
NL-Goes-ADRZ, Goes
RECRUITING
NL-Groningen-UMCG, Groningen
RECRUITING
NL-Hoofddorp-SPAARNEGASTHUIS, Hoofddorp
RECRUITING
NL-Leeuwarden-MCL, Leeuwarden
RECRUITING
NL-Maastricht-MUMC, Maastricht
RECRUITING
NL-Rotterdam-ERASMUSMC, Rotterdam
RECRUITING
NL-Den Haag-HAGA, The Hague
Danish Lymphoma Group
UNKNOWN
Stichting Hemato-Oncologie voor Volwassenen Nederland
OTHER